INKT cell culture method

By directly induced culture, PBMCs were isolated and precoated monoclonal antibodies and complete culture medium were used to solve the problems of low purity and insufficient quantity in iNKT cell culture, and efficient and simple preparation of iNKT cells was achieved, with extremely high clinical transformation value.

CN118995602APending Publication Date: 2024-11-22BEIJING QINGMEI LIANCHUANG STEM CELL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411434043.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-15
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

In the prior art, iNKT cell culture has problems such as low purity, insufficient quantity, complex operation and high cost, which limits its application in cell therapy.

Method used

PBMCs were isolated by direct induction culture, using precoated monoclonal antibodies and complete medium, including X-Vivo 15 basal medium, IL-2, IL-21, α-GalCer, and purified by anti-iNKT microbeads, avoiding DC cells The use of the simplified operation and improved cell purity and quantity.

Benefits of technology

Up to 95% of the purity of iNKT cells and the number of cells above 1 billion were obtained, reducing the difficulty and cost of purification operations, and improving the killing activity and clinical application value of cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995602A_ABST
    Figure CN118995602A_ABST
Patent Text Reader

Abstract

The invention discloses an iNKT cell culture method. The method comprises the following steps: (1) pre-coating a culture vessel with an iNKT cell monoclonal antibody; (2) separating and purifying a mononuclear cell PBMC from peripheral blood; (3) laying the PBMC in a culture vessel pre-coated with the monoclonal antibody, and adding a complete culture medium; (4) purifying the iNKT cells by utilizing the anti-iNKT microbeats, and carrying out the purification on the iNKT cells; and (5) carrying out amplification culture on the purified iNKT cells. The obtained iNKT cells are high in purity, few in impurities and good in tumor target cell killing effect. The final amplification multiple of the iNKT cells is up to more than million times and reaches at least 109 orders of magnitude, and a good foundation is laid for adoptive treatment of the iNKT cells and subsequent product research.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of cell immunotherapy, and specifically relates to an iNKT cell culture method. Background Art

[0002] iNKT cells (invariant natural killer T cells) are a special type of T cell that connects innate and acquired immunity.

[0003] In addition to surgery, chemotherapy, and radiotherapy, clinical cancer treatment methods have seen an increasing use of biological treatment technology in recent years, including monoclonal antibody technology, cytokines, tumor vaccines, immune cells, etc., especially immune cell tumor treatment technology, which has received widespread attention and attention with the success of CAR-T in the treatment of large B-cell lymphocytic leukemia. Cell therapy for cancer has gradually come into people's view.

[0004] At present, there are five CAR-T drugs on the market in China: Fosun Kite's Akirensel Injection, Innovent Biologics' Ruikiorensel Injection, Innovent Biologics' Ikiorensel Injection jointly developed by Innovent and Reindeer Biopharmaceuticals, Heyuan Biopharmaceuticals' Nakiorensel Injection, and Coherus Pharmaceuticals' Zewokiorensel. Chongqing Precision Biopharmaceuticals' Pukiorensel Injection is applying for listing. These drugs are mainly used to treat large B-cell lymphoma, multiple myeloma, B-cell acute lymphoblastic leukemia and other blood system tumors. Cell drugs for solid tumors have not yet appeared, and the main obstacle is how to make cell drugs break through the tumor microenvironment and achieve the purpose of treatment.

[0005] The types of cell drugs for solid tumors that have entered clinical trials or are in preclinical development are mainly concentrated in CAR-T and CAR-NK cells, and a few research teams are engaged in the development and research of functional cells such as CAR-iNKT, CAR-γδT, and CAR-M (macrophages). CAR-T and CAR-NK cells have their own disadvantages.

[0006] 1. CAR-T cells are effective in treating leukemia, but the effect on solid tumors is not ideal, and there is also a risk of "cytokine storm". Secondly, after CAR-T cells interact with tumor cells, both tumor cells and CAR-T cells will express "immune checkpoint molecules", further limiting the effect of CAR-T cells. Third, since T cells are tissue-specific, allogeneic transfusions cannot be performed between different individuals. Due to the physical constitution of some tumor patients, autologous T cells cannot be cultured well, which makes CAR-T culture difficult and limits the application of CAR-T cells.

[0007] 2. CAR-NK cells. NK cells are a natural defensive immune cell that can play the body's immune surveillance function. Although NK cells are different from T cells and are not restricted by MHC and can be transfused allogeneically, the preparation of CAR-NK cells has a bottleneck of low efficiency of lentivirus infection of NK cells. At present, after lentivirus infection of NK cells, the highest CAR positive rate is only about 10%, which greatly reduces the killing effect of CAR-NK cells.

[0008] In view of the above limitations of CAR-T and CAR-NK cells, many research and development teams hope to develop a new type of immune cell that can have both the high killing activity of T cells and the high vitality of NK cell functions, namely NKT cells. NKT cells are divided into three categories: type I NKT cells, i.e. iNKT cells; type II NKT cells; type III NKT cells, i.e. NK-like T cells. iNKT cells account for a very low proportion in the body, accounting for less than 0.1% of PBMCs, and in vitro cultivation of iNKT cells is currently a major technical bottleneck, limiting its wide application.

[0009] 1. Natural iNKT cells can recognize tumor tissues or cells expressing CD1d and then kill these tumor cells. After modification with chimeric antigens, the obtained CAR-iNKT recognizes tumor tissues or cells through antibody targeting. The CAR-iNKT tumor cell killing effect is "superimposed" with the natural iNKT cell effect, which is more effective in killing tumor tissues or cells.

[0010] 2. The mechanism of iNKT cell recognition of tumor antigens is different from that of T cells. iNKT cells recognize glycolipid antigens presented by tumor cell CD1d, not HLA-presented antigens, so CAR-iNKT cells are non-MHC-restricted and can be allogeneically infused. Studies have reported that iNKT cells can be used for allogeneic immunotherapy and have significant clinical application value. In recent years, more clinical trial research data have shown that iNKT cell adoptive immunotherapy for tumors has no obvious side effects and has very good clinical application prospects.

[0011] 3. iNKT cells have an important immunomodulatory effect. When CAR-iNKT interacts with tumor cells, in addition to expressing and secreting factors related to tumor killing, such as granzymes, perforins, TNF-a, etc., it also secretes some immunomodulatory factors, such as IFN-γ, IL-2, IL-12, IL-4 and other cytokines. IFN-γ participates in Th1 induction and promotes IL-2 secretion; at the same time, it inhibits the differentiation function of Th2 cells. IL-12 can further positively induce NKT cells to produce more IFN-γ, enhancing the body's anti-tumor effect.

[0012] CN117511868A discloses a method for realizing rapid expansion of iNKT cells. The method comprises the following steps: firstly, the peripheral blood mononuclear cells are inoculated into a culture dish, and a culture medium containing α-Galcer, Eucheuma polypeptide and IL-2 is added; then, the cells are placed in a cell culture incubator at 37°C and 5% CO2 for culture; then, new culture medium containing α-Galcer, Eucheuma polypeptide and IL-2 is added every 3 days to adjust the cell concentration to 2×10 6 / mL; after culturing for 12-14 days, the cells are collected and purified to obtain iNKT cells. It is said that the iNKT obtained using this method has high proliferation ability and high killing activity. However, the cells obtained using this patented culture method are not accurately defined as iNKT cells, and the number of cells finally obtained is unknown.

[0013] CN116716246A discloses a method and application of in vitro expansion and induced activation of umbilical cord blood iNKT cells. The method comprises the following steps: expansion phase: obtaining umbilical cord plasma resuspended cell pellet containing iNKT cells from umbilical cord blood, adding 1640 basal culture medium, IL-2, IL-15, KDM2B and 10vol% of the umbilical cord plasma resuspended cell pellet to the cell culture bottle to expand iNKT cells; induction activation phase: after the expansion of iNKT cells is completed, adding X-VIV0 10 ​​culture medium, ConA and a-GalCer to induce iNKT cell activation and maturation. The invention cultured and expanded iNKT cells and induced activation respectively, thereby improving the expansion efficiency and biological activity of iNKT cells, and the number of cells obtained is sufficient. The cells obtained by the patented culture technology are CD3+CD56+ double positive NKT cells.

[0014] CN117187178A discloses a culture medium and a method for amplifying iNKT cells, wherein the culture medium does not need to add antigen presenting cells (APCs), does not need to add α-galactosylceramide (α-GalCer) or its derivatives, and only contains serum-free, human or animal-derived cell culture medium and recombinant cytokines. The culture medium and amplification method of the invention are used for cultivation, which can make iNKT cells expand by more than millions of times after 28 days of cultivation, and the purity of iNKT cells can reach more than 95%, meeting the needs of clinical treatment and having a high prospect of clinical transformation. The patented iNKT cell culture technology has a long total culture cycle, a high difficulty in cell purification operation and a high purification cost.

[0015] CN116590229A discloses a culture method for improving the killing ability of human iNKT cells. The method uses monocytes as starting cells and cultures them in a culture container coated with anti-human Vα24-Jα18TCR antibodies. Intermittent stimulation is used during the culture process. The method obtains a large number of iNKT cells, which can achieve a purity of more than 70% of iNKT cells in a serum-free culture medium, an amplification multiple of about 150,000 times, and its killing ability is very excellent. The simplified culture method used in the invention does not require the use of feeder cells or magnetic beads that complicate the culture system and increase the cost, and the cost is low. iNKT cells are TCR V alpha24 and TCR V beta 11 double-positive cells. In addition, they also weakly express antigens such as NKG2D, NKp46, and CD16. However, the cell purity obtained by the patent is low, and the number of cells finally obtained is only in the hundreds of millions.

[0016] CN107502591A discloses a concentration gradient rhIL-2-dependent iNKT cell expansion method and its application. The method comprises (1) extracting peripheral blood mononuclear cells PBMC; adding α-GalCer with a final concentration of 100ng / ml to the PBMC cells extracted in step (1) and culturing for 48 hours; gradually increasing the rhIL-2 concentration in the culture medium in a gradient manner in the cultured cells in step (2). iNKT cells are harvested on the 21st day of culture, and the number of iNKT cells increases by 100,000 times, of which more than 90% are CD4-iNKT cells, which have the effects of upregulating immune response and directly killing tumors. The iNKT cells activated and amplified by the method of the invention have higher amplification efficiency, selectively amplify Th1-like iNKT cells, and enhance the functions of in vitro amplification of iNKT cells for immune enhancement, tumor immune monitoring and killing. However, the patent requires the additional addition of DC cells to PBMC when inducing and culturing iNKT cells, and DC cells need to be prepared in advance, and more peripheral blood is required, which greatly increases the complexity of the operation steps and the culture cycle. Summary of the invention

[0017] The purpose of the present invention is to overcome the problems existing in the above-mentioned prior art and provide an iNKT cell culture method, which directly induces and cultures the isolated PBMCs without the need for DC cells, and the purity of the iNKT cells finally obtained is as high as more than 95%, the number of cells finally obtained is more than 1 billion, and the difficulty of cell purification operation is greatly reduced and the purification cost is saved.

[0018] The method of the present invention comprises the following steps: (1) The culture vessel is pre-coated with iNKT cell monoclonal antibody; (2) Isolation and purification of mononuclear cells (PBMCs) from peripheral blood; (3) PBMCs were plated in a culture dish pre-coated with monoclonal antibodies and complete culture medium was added. The culture medium components included X-Vivo 15 basal medium, IL-2, IL-21, and α-GalCer. (4) Purification of iNKT cells using anti-iNKT microbeads; (5) Expanding and culturing the purified iNKT cells, wherein the culture medium components include X-Vivo 15 basal medium, IL-2, IL-7, and blood replacement, and culturing to the 9th to 15th day, for example, the 10th day, the 11th day, and the 12th day.

[0019] Preferably, the mononuclear cells PBMC are separated and purified from peripheral blood using a lymphocyte separation solution Ficoll.

[0020] Preferably, the peripheral blood is adult peripheral blood.

[0021] The present invention is to culture iNKT cells in a vessel pre-coated with monoclonal antibodies, wherein the pre-coated monoclonal antibodies refer to iNKT cell monoclonal antibodies, which can be selected from any one of the four monoclonal antibodies of NKG2D, NKp46, TCR V beta11, and CD16, and TCR V beta11 is more preferred.

[0022] The preferred pre-coated monoclonal antibody concentration is 50 ng / ml-10 μg / ml, further 100 ng / ml-500 ng / ml or 100 ng / ml-1 μg / ml.

[0023] Preferably, the mononuclear cells (PBMC) are separated and purified from peripheral blood using the lymphocyte separation fluid Ficoll by gradient density centrifugation. Preferably, the PBMC obtained by gradient density centrifugation must be treated with erythrocyte disruption. The PBMC cells are treated with sterile water for 10-20 seconds.

[0024] The preferred iNKT cell complete culture medium includes IL-2, IL-21, and α-GalCer. The basal culture medium is X-Vivo 15. FBS may also be optionally included, and the preferred final concentration of FBS is 5-15wt%, preferably about 10wt%.

[0025] The preferred final concentration of IL-2 is 50-150 IU / ml, further preferably 80-120 IU / ml, and more preferably 100 IU / ml.

[0026] The preferred final concentration of IL-21 is 3-10 ng / ml, preferably about 5 ng / ml.

[0027] The preferred final concentration of α-GalCer is 50-150 ng / ml, preferably about 100 ng / ml.

[0028] The optimal PBMC culture concentration is 1~2.5×10 6 / ml.

[0029] Preferably, purification is performed using anti-iNKT microbeads.

[0030] The preferred iNKT cell expansion medium includes IL-2, IL-7, hemoglobin (UltraGRO), and the basal medium is X-Vivo 15.

[0031] The preferred final concentration of IL-2 is 50-150 IU / ml, further preferably 80-120 IU / ml, and more preferably 100 IU / ml.

[0032] The preferred final concentration of IL-7 is 5-15 ng / ml, more preferably about 10 ng / ml.

[0033] The preferred final concentration of UltraGRO is 2.0-3.0 v / v%, more preferably about 2.5 v / v%.

[0034] The optimal concentration of iNKT cells during expansion culture is 1~2×10 6 / ml.

[0035] The main advantages of this patent are: first, this patent does not require the addition of DC cells as feeder cells, but directly adds PBMC cells to the culture vessel coated with TCR V beta11 antibody to induce and culture iNKT cells, which is simple to operate and greatly reduces the iNKT cell culture cycle; second, this patent can eventually obtain more than 1 billion clinical-grade iNKT cells, which have excellent target cell killing effects and extremely high clinical transformation value; third, this patent uses serum-free culture medium when expanding culture to avoid animal-derived components; fourth, after the initial induction and culture of iNKT cells, the iNKT cell purification operation is optimized, the purity of iNKT cells is improved, impurities are reduced, and the incidence of clinical treatment side effects is effectively reduced. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 The results of flow cytometry analysis of iNKT cell phenotype: A is normal healthy human peripheral blood PBMC cells; B is the cells on Day 10 after stimulation and induction by the common method; C is the cells on Day 10 after stimulation and induction by the method of the present invention; D is the cells after microbeads sorting; E is the cells on Day 9 of expanded culture.

[0037] Figure 2 This is a curve chart of CD1d analysis results by flow cytometry: A is THP-1 cells; B is K562 cells.

[0038] Figure 3 The curve diagram of iNKT cells killing target cells in vitro was analyzed by the LDH method.

[0039] Figure 4 The bar graph shows the cytokine secretion levels when iNKT cells kill target cells using the ELISA method: A is the IFN-γ concentration; B is the IL-4 concentration.

[0040] Figure 5 This is a graph showing the results of measuring the proliferation curve of iNKT cell expansion culture. DETAILED DESCRIPTION

[0041] The present invention is further described in detail below through specific examples.

[0042] The reagents used in the examples of the present invention are described as follows: Miltenyi Biotec: TCR V beta11, anti-iNKT microbeads, FcR inhibitor, Dead cell removal kit Lonza: X-Vivo 15 Tianjin Haoyang: Lymphocyte separation fluid Invitrogen: CD3-FITC, anti-iNKT-PE PrimeGene: IL-7, IL-21 Jiangsu Jinsili: IL-2 MCE: a-GalCer. Example 1

[0043] 1. PBMC Isolation and Purification 1. Collect donor peripheral blood, add an equal volume of PRMI1640 culture medium, mix gently, add Ficoll solution in a 2:1 ratio in a 50ml centrifuge tube, and then slowly add the diluted whole blood; 2. Centrifuge at 1800 rpm for 20 min and use a disposable pipette to aspirate mononuclear cells from the buffy coat layer; 3. Add at least 5 times the volume of RPMI1640 medium, centrifuge at 1500rpm for 10min, and remove the supernatant; 4. Combine all the precipitates with 10 ml RPMI1640 medium, transfer to a 15 ml centrifuge tube, centrifuge at 800 rpm for 10 min, and remove the supernatant; 5. Resuspend the precipitate with 1 ml of sterile water, let stand for 10 seconds, add RPMI1640 medium to 50 ml, centrifuge at 1000 rpm for 10 minutes, and remove the supernatant; 6. Add NKT complete medium to resuspend the cell pellet to a single cell suspension, count, and analyze the proportion of iNKT cells by flow cytometry. The results are shown in Figure 1 A.

[0044] 2. PBMC cell culture 1. The culture vessel was pre-coated with 100 ng / ml monoclonal antibody TCR V beta11; 2. Prepare NKT complete medium by adding 100 IU / ml IL-2, 5 ng / ml IL-21, and 100 ng / ml a-Galcer to X-Vivo 15 basal medium; 3. Add the PBMC cell suspension to a vessel pre-coated with 100 ng / ml monoclonal antibody TCR V beta11, with a concentration of 2.5×10^6 / ml, and place in a 37°C, 5% CO2 incubator, which is counted as Day 0; 4. Add equal volumes of fresh culture medium on Day 3, Day 5, and Day 7, and replace half of the medium on Day 9; 5. Collect cells on Day 10, centrifuge at 1000 rpm for 10 min, remove supernatant, add 2 ml RPMI1640 medium to resuspend cells into single cell suspension, and count; Flow cytometry was used to analyze the proportion of iNKT cells. Figure 1 B, C.

[0045] (III) Magnetic bead purification Centrifuge at 1000 rpm for 10 min, add reagents and operate according to the instructions of anti-iNKT microbeads. Resuspend the obtained iNKT cells in NKT expansion medium and count them.

[0046] Flow cytometry was used to analyze the proportion of iNKT cells. Figure 1 D.

[0047] 4. iNKT cell expansion culture 1. Prepare NKT expansion medium by adding 100 IU / ml IL-2, 10 ng / ml IL-7, and 2.5% UltraGRO to X-Vivo 15 basal medium; 2. Add the iNKT cell suspension obtained in (III) magnetic bead purification to the vessel at a concentration of 1×10^6 / ml and place in a 37°C, 5% CO2 incubator, which is counted as Day 0; 3. On Day 2 and Day 4, add equal volumes of fresh expansion medium. On Day 5, collect cells into a larger dish and add 1.5 times the volume of fresh expansion medium. On Day 7, add 1.5 times the volume of fresh expansion medium. 4. Collect cells on Day 9.

[0048] Flow cytometry was used to analyze the proportion of iNKT cells. Figure 1 E. The changes in the number of iNKT cells during the entire process of proliferation and culture are shown in Table 1.

[0049] Table 1 Changes in the number of iNKT cells during the entire process of proliferation and culture

[0050] Figure 1 The results of flow cytometer analysis showed that the iNKT cells induced by this patent have increased from almost undetectable in PBMC to 32.7% after initial culture, while the ordinary culture method only increased to 6.94%, which is much better than the ordinary culture technology. After optimizing the purification method, the purity of the purified iNKT cells reached 96.5%. After the expanded culture of the purified iNKT cells, the purity was 94.8%, reaching the clinical application level.

[0051] Experimental Example 1 iNKT cells kill THP-1 and K562 cells 1. Resuscitation of THP-1 cells and K562 cells; flow cytometry analysis of CD1d percentage; results are shown in Figure 2 A and 2B; 2. Take appropriate amount of THP-1 cells and K562 cells, add 100 ng / ml a-Galcer and culture for 24 h; 3. Design a 96-well plate killing scheme according to the CK-12 instruction manual; set the effector-target ratio to 8:1, 4:1, 2:1, 1:1, 1:2, 1:4, 1:8, and set high control, high control Blank, low control, and low control Blank at the same time, and make 2 duplicate wells; add corresponding iNKT cells and target cells according to the scheme and culture them for 24 hours; 4. Detect the OD value of each well according to the CK-12 instruction manual. The results of iNKT cells killing tumor cells are shown in Figure 3 .

[0052] The kill rate is calculated using the following formula: A = Sample well OD value - Sample well Blank OD value B = high control OD value - high control Blank OD value C = low control OD value - low control Blank OD value Kill rate (%) = (AC) ÷ (BC) × 100.

[0053] from Figure 2 The results showed that THP-1 cells highly expressed CD1d, while K562 cells lowly expressed CD1d. Figure 2 and Figure 3The results showed that natural iNKT cells cultured in vitro could efficiently kill THP-1 cells with high expression of CD1d, but had limited killing effect on K562 cells with low expression of CD1d.

[0054] Experimental Example 2 Detection of cytokine release by co-culture of iNKT cells and target cells The supernatant with the effector-target ratio of 8:1, 4:1, 2:1, and 1:1 in the above-mentioned "iNKT cells killing THP-1 and K562 cells" was selected and operated according to the instructions of the kit. For specific ELISA results, see Figure 4 , Figure 4 A is the result of IFN-γ secretion expression when iNKT cells kill THP-1 and K562 cells. Figure 4 B shows the results of IL-4 secretion and expression when iNKT cells kill THP-1 and K562 cells. Figure 4 The results showed that iNKT cells could kill THP-1 cells, which secreted and expressed IFN-γ at high levels and IL-4 at moderate levels.

[0055] Experimental Example 3 iNKT cell proliferation curve determination In a 96-well plate, 5×10^3 iNKT cells and 200ul culture system were added to each well. On Day 0, Day 2, Day 4, Day 6, Day 8, and Day 9, OD values ​​were detected according to the instructions of the CCK-8 kit, and cell counting was performed at the same time. Two replicates were made for each well. For specific results, see Figure 5 .

[0056] from Figure 5 The results showed that the proliferation rate of iNKT cells began to accelerate on the third day after the purified cells were expanded and cultured, and exponential proliferation occurred after the fourth day. The number of cells reached a plateau on the ninth day, but the cell activity began to decline. Therefore, the iNKT cells can be collected on the eighth day after the expansion culture for later operation.

[0057] Finally, it should be noted that the above content is only for illustrative purposes and not for limiting the scope of protection of the present invention. A person skilled in the art may modify or substitute equivalents for the technical solution of the present invention without departing from the essence of the present invention, and the modifications or equivalent substitutions shall be included in the scope of protection of the claims of the present invention.

Claims

1. A method for culturing iNKT cells, characterized in that: The following steps are involved: (1) The culture vessel is pre-coated with iNKT cell monoclonal antibody; (2) Isolation and purification of mononuclear cells (PBMCs) from peripheral blood; (3) PBMCs were plated in a culture dish pre-coated with monoclonal antibodies and complete culture medium was added. The culture medium components included X-Vivo 15 basal medium, IL-2, IL-21, and α-GalCer. (4) Purification of iNKT cells using anti-iNKT microbeads; (5) The purified iNKT cells were expanded and cultured in a medium containing X-Vivo 15 basal medium, IL-2, IL-7, and blood substitute until the 9th to 15th day.

2. The method according to claim 1, characterized in that The iNKT cell monoclonal antibodies in step (1) include five monoclonal antibodies: NKG2D, NKp46, TCR V beta11, and CD16.

3. The method according to claim 1 or 2, characterized in that: The concentration of the iNKT cell monoclonal antibody is 50 ng / ml-10 μg / ml.

4. The method according to claim 3, characterized in that: The iNKT cell monoclonal antibody concentration was 100 ng / ml.

5. The method according to claim 1, characterized in that The peripheral blood in step (2) is adult peripheral blood.

6. The method according to claim 1, characterized in that In the step (2), PBMCs are treated with erythrocyte disruption.

7. The method according to claim 1, characterized in that In step (3), the final concentration of IL-2 is 80-120 IU / ml, the final concentration of IL-21 is 3-10 ng / ml, and the final concentration of a-GalCer is 50-150 ng / ml.

8. The method according to claim 7, characterized in that In step (3), the final concentration of IL-2 is 100 IU / ml, the final concentration of IL-21 is 5 ng / ml, and the final concentration of a-GalCer is 100 ng / ml.

9. The method according to claim 1, characterized in that: In step (5), the final concentration of IL-2 is 80-120 IU / ml, the final concentration of IL-7 is 5-15 ng / ml, and the final concentration of hemoglobin is 2.0-3.0%.

10. The method according to claim 9, characterized in that In step (5), the final concentration of IL-2 is 100 IU / ml, the final concentration of IL-7 is 10 ng / ml, and the final concentration of hemoglobin is 2.5%.